Harvard Bioscience earnings were -$10.4M for the trailing 12 months ending Jun 30, 2026, with N/A growth year over year. The latest HBIO earnings report on Jun 30, 2026 announced Q2 2026 earnings of -$2.9M, down 15% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, HBIO reported annual earnings of -$56.7M, with 357.1% growth. The next HBIO earnings date is Nov 5, 2026.
What were Harvard Bioscience's earnings last quarter?
On HBIO's earnings call on Aug 11, 2026, Harvard Bioscience (NASDAQ: HBIO) reported Q2 2026 earnings per share (EPS) of -$0.64, up 23.08% year over year. Total HBIO earnings for the quarter were -$2.91 million. In the same quarter last year, Harvard Bioscience's earnings per share (EPS) was -$0.52.
The next HBIO earnings date is Nov 5, 2026. Add HBIO to your watchlist to be reminded of Harvard Bioscience's next earnings date.
Is Harvard Bioscience profitable or losing money?
As of the last Harvard Bioscience earnings report, Harvard Bioscience is currently losing money. Harvard Bioscience's net profit (also called net income) for the twelve months ending Jun 30, 2026 was -$10.41 million, a 81.86% decrease year over year.
What was HBIO's earnings growth in the past year?
As of Harvard Bioscience's earnings date in Aug 11, 2026, Harvard Bioscience's earnings has grown year over year. HBIO earnings in the past year totalled -$10.41 million.
What are Harvard Bioscience's earnings expectations?
The current EPS estimate for Harvard Bioscience's earnings report in Nov 5, 2026 is -$0.17.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.